Next Article in Journal
Functional Ex Vivo Testing of Alveolar Monocytes in Patients with Pneumonia-Related ARDS
Previous Article in Journal
Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease
Previous Article in Special Issue
Treatment with Autophagy Inducer Trehalose Alleviates Memory and Behavioral Impairments and Neuroinflammatory Brain Processes in db/db Mice
Review

Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease

1
Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université de Paris, 75006 Paris, France
2
Service de Neurologie, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
3
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, 67400 Illkirch, France
4
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, 67000 Strasbourg, France
5
CNRS and Strasbourg University, Unit Biotechnology and Cell Signaling/Strasbourg Drug Discovery and Development Institute (IMS), 67000 Strasbourg, France
6
University of Strasbourg Institute for Advanced Study (USIAS), 67000 Strasbourg, France
*
Authors to whom correspondence should be addressed.
Academic Editors: Ciro Isidoro and Tatiana A. Korolenko
Cells 2021, 10(12), 3547; https://doi.org/10.3390/cells10123547
Received: 22 November 2021 / Revised: 13 December 2021 / Accepted: 13 December 2021 / Published: 15 December 2021
(This article belongs to the Special Issue State-of-Art in Autophagy and Neurodegeneration)
Cellular quality control systems have gained much attention in recent decades. Among these, autophagy is a natural self-preservation mechanism that continuously eliminates toxic cellular components and acts as an anti-ageing process. It is vital for cell survival and to preserve homeostasis. Several cell-type-dependent canonical or non-canonical autophagy pathways have been reported showing varying degrees of selectivity with regard to the substrates targeted. Here, we provide an updated review of the autophagy machinery and discuss the role of various forms of autophagy in neurodegenerative diseases, with a particular focus on Parkinson’s disease. We describe recent findings that have led to the proposal of therapeutic strategies targeting autophagy to alter the course of Parkinson’s disease progression. View Full-Text
Keywords: autophagy; lysosomes; neurodegenerative disease; Parkinson’s disease; autoimmunity autophagy; lysosomes; neurodegenerative disease; Parkinson’s disease; autoimmunity
Show Figures

Figure 1

MDPI and ACS Style

Bonam, S.R.; Tranchant, C.; Muller, S. Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease. Cells 2021, 10, 3547. https://doi.org/10.3390/cells10123547

AMA Style

Bonam SR, Tranchant C, Muller S. Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease. Cells. 2021; 10(12):3547. https://doi.org/10.3390/cells10123547

Chicago/Turabian Style

Bonam, Srinivasa R., Christine Tranchant, and Sylviane Muller. 2021. "Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease" Cells 10, no. 12: 3547. https://doi.org/10.3390/cells10123547

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop